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Artificial Metalloenzymes for
Enantioselective Catalysis Based on the
Biotin-Avidin Technology
Jincheng Mao and Thomas R. Ward*
Abstract: Artificial metalloenzymes, based on the incorporation of a biotinylated catalytically active organometallic
moiety within streptavidin, offer an attractive alternative to homogeneous, heterogeneous and enzymatic catalysis.
In this account, we outline our recent results and implications in the developments of such artificial metalloenzymes
for various asymmetric transformations, including hydrogenation, transfer hydrogenation, allylic alkylation and
sulfoxidation.
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With the aim of complementing the
well-established fields of homogeneous and
enzymatic catalysis, organocatalysis and
artificial metalloenzymes have witnessed a
recent revival.
[4,5]
Artificial metalloenzymes
result from the combination of an active but
unselective organometallic moiety with a
macromolecular host (protein or DNA) as
shown in Fig. 1.
Both Kaiser and Whitesides suggested
the possibility of creating artificial metal-
loenzymes in the late 1970s.
[6,7]
However, at
that time there was a widespread belief that
proteins and organometallic catalysts are
incompatible with each other. This severely
hampered research in this area at the inter-
face between homogeneous and enzymatic
catalysis.
[8]
Since 2000 however, there has
been increasing interest in the field of arti-
ficial metalloenzymes for enantioselective
catalysis.
[9–13]
For the localization of an organometal-
lic moiety within a macromolecular host,
three anchoring strategies can be envisaged:
covalent, dative or supramolecular.
[5]
Using
such approaches, enantioselective artificial
metalloenzymes have been created for hy-
drolysis,
[12]
hydrogenation,
[14–17]
transfer
hydrogenation,
[18]
allylic alkylation,
[19]
sulfoxidation,
[20–24]
epoxidation,
[25,26]
dihy-
droxylation,
[27]
Diels-Alder,
[28,29]
trans-am-
ination,
[30]
Michael addition
[31]
and fluori-
nation.
[32]
Comparatively, supramolecular
anchoring appears as the most appealing,
since it allows separate variation of both
biological and chemical components, fol-
lowed by straightforward combination of
the organometallic moiety and the macro-
molecular host. In addition, no chemical
modification step is required after the in-
corporation of the catalyst precursor, thus
ensuring the integrity of the organometal-
lic species. In recent years, we have been
exploiting the biotin-avidin technology for
the creation of artificial metalloenzymes
for enantioselective catalysis. Herein we
summarize the challenges and our progress
in this area.
Results and Discussion
The Biotin-Avidin Technology
The biotin-avidin technology, often re-
ferred to as molecular velcro, relies on the
very high affinity of biotin for either avidin
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Introduction
In order to meet the ever-increasing de-
mand for enantiopure compounds, hetero-
geneous-, homogeneous- and enzymatic
catalysis have evolved independently in the
past years.
[1,2]
Although all three approaches
have yielded industrially viable processes,
the latter two are the most widely used and
can be regarded as complementary in many
respects.
[3]
Despite the progress in structur-
al, computational and mechanistic studies
however, there exists to date no universal
recipe for the optimization of a catalytic
process. Thus, a trial-and-error approach
remains predominant in catalyst discovery
and optimization.
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Fig. 1. Anchoring a catalytically active but
unselective organometallic catalyst within a
host protein affords artiﬁcial metalloenzymes for
enantioselective catalysis. Chemical optimization
can be achieved either by varying the spacer
(oval) or the chelating ligand. Site-directed or
random mutagenesis at a position close to the
metal moiety (*) can be used for the genetic
optimisation.
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or streptavidin – (strept)avidin hereafter.
[33]
The versatility of this technology can be
traced back to the following features:
i) The nearly irreversible interaction be-
tween biotin and (strept)avidin relies
solely on hydrogen bonds and hydro-
phobic interactions and thus can reli-
ably take place in a variety of environ-
ments (cell, blood, surfaces etc.) under
mild conditions (Fig. 2).
ii) A straightforward amide bond-forming
reaction allows a biotin moiety to be
appended to nearly any probe. This de-
rivatization of the valeric acid side chain
of biotin does not significantly affect
the high affinity of the biotin-avidin
couple.
[34]
iii) (Strept)avidin possesses a homote-
trameric β-barrel structure with four
equivalent biotin-binding sites. This al-
lows different moieties to be brought in-
to close proximity via the biotin-avidin
technology.
iv) (Strept)avidin is a very robust protein
scaffold which can be easily handled by
inexperienced chemists without the risk
of losing biotin-binding activity.
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Fig. 2. Interactions responsible for the biotin-
streptavidin afﬁnity (K
a
ca. 10
14
M
–1
). In addition
to the hydrogen-bonding network, the biotin-
binding site is lined with four tryptophane
residues, one of which, Trp 120, is provided by
the adjacent streptavidin monomer.
In the past four decades, this versatile
tool has found numerous applications in
affinity chromatography, signal amplifica-
tion, drug delivery, immunoassays, immo-
bilization etc.
[35]
Inspired by the pioneering work of the
Whitesides group,
[7,17]
we reasoned that we
could exploit the biotin-avidin technology
for the creation and optimization of artificial
metalloenzymes. Introductionofabiotinan-
chor on a chelating ligand ensures the local-
ization of an organometallic moiety within
a chiral environment provided by (strept)
avidin. We endeavored to use modern tools
of genetic and chemical optimization to
fine-tune the second coordination sphere of
the resulting artificial metalloenzymes. The
main stages include i) mutation and overex-
pression of the (strept)avidin isoform in a
suitable host, ii) isolation, purification and
quantification of the activity of the mutated
(strept)avidin, iii) synthesis of the biotiny-
lated catalyst precursor and incorporation
within (strept)avidin, iv) catalysis, and v)
product isolation and analysis.
One of the most attractive features of
this approach is the diversity generated
by combining both chemical and genetic
optimization strategies.
[36]
Following this
approach, we have been able to develop ar-
tificial metalloenzymes for the hydrogena-
tion, the allylic alkylation and the transfer
hydrogenation reaction.
The Chemical Optimization Dimension
In the spirit of homogeneous catalyst
optimization, variation of the first coordina-
tion sphere provided by a chelating ligand
often has a significant impact on the perfor-
mance of the resulting catalyst. Inspired by
some of the best homogeneous catalysts, a
series of aminodiphosphines and aminosul-
fonamides were synthesized and coupled
with the biotin-anchor. We reasoned that
introduction of a spacer between the biotin
and the chelating ligand would project a dif-
ferent chiral environment for each biotin-
spacer-ligand combination, thus offering
a straightforward optimization strategy.
The most versatile ligands and spacers are
shown in Fig. 3.
The Genetic Optimization Dimension
Considering the ease of recombinant
protein production in various hosts, we set
out to produce streptavidin (Sav hereafter)
in Escherichia coli and avidin (Avi hereaf-
ter) in Pichia pastoris.
[37,38]
Although in our
hands both proteins could be overexpressed
to high levels (230 mg·l
–1
cell culture and
330 mg·l
–1
cell culture respectively) strepta-
vidin was eventually preferred over avidin
for the following reasons:
i) In contrast to streptavidin, avidin is gly-
cosylated. This is a source of inhomo-
geneity and thus may cause reproduc-
ibility concerns. In addition, the inho-
mogeneity renders crystallization more
challenging.
ii) Each avidin monomer possesses a sin-
gle intramolecular disulfide bridge. As a
consequence, the protein cannot be de-
natured and renatured, which is a limita-
tion for purification purposes.
iii) E. coli is a well behaved and a very easy
to handle organism for the overexpres-
sion of recombinant proteins. However,
it should be emphasized that P. pastoris
secretes the recombinant proteins in the
culture medium, which could be a major
asset for future directed evolution stud-
ies.
In light of the above reasons and consid-
ering that our initial success was obtained
with streptavidin rather than avidin,
[14]
we
rapidly focused on streptavidin and mu-
tants thereof as host for artificial metal-
loenzymes.
Docking studies performed with either
[Rh(COD)(Biot–1)]
+
or [Ru(η
6
-arene)
H(Biot–III
p
–2)] within WT-Sav revealed
that the potential energy surface describ-
ing the localization of the metal within the
protein environment was flat and the metal
adopted different positions within a very
small energy window.
[39,40]
Analysis of the
C
α
–M distances revealed that the asym-
metric carbon (C
α
) of residue S112 Sav lay
systematically closest to the metal center.
Based on these in silico studies, we set out
to produce all twenty Sav isoforms result-
ing from saturation mutagenesis at posi-
tion S112X Sav.
[41]
Except for S112P Sav
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Fig. 3. Chemical diversity generated by combining different biotinylated
spacers and ligands. After addition of a suitable metal source, the resulting
biotinylated organometallic catalyst precursors are combined with (strept)
avidin to afford artiﬁcial metalloenzymes.
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(which afforded low levels of pure protein),
all mutants could be produced in high yield
and purified from 10 liter E coli fermenta-
tions.
Artificial Hydrogenases
Having synthesized a library of bioti-
nylated diphosphine ligands, these were re-
acted with [Rh(COD)]
+
and combined with
a Sav isoform. The resulting artificial met-
alloenzymes were screened for the reduc-
tion of N-acetamidodehydroalanine and N-
acetamidodehydrophenylalanine to afford
N-acetamidodehydroalanine (N-AcAla)
and N-acetamidophenylalanine (N-AcPh)
respectively (Scheme 1). Overall, twenty-
two ligands were screened in the presence
of the twenty Sav isoforms and WT Avi.
Noteworthy results are collected in Table
1.
[14,41–45]
Based on these data, the follow-
ing trends can be identified:
i) Both (R)- and (S)-enantiomers of the
product can be obtained in good enan-
tioselectivities (> 90% ee, Table 1. en-
tries 1–6)
ii) Chemical diversity (e.g. variation of the
spacer) is a more versatile means for op-
timization that genetic diversity. This lat-
ter can be regarded as a fine tuning step.
iii) Introduction of conformationally con-
strained spacers (e.g. proline IV) confers
significant organic solvent tolerance to
the systems. Both biphasic and dmso/wa-
ter mixtures yield good conversions and
selectivities (Table 1, entries 3–5).
[45]
iv) The artificial hydrogenases follow Mi-
chaelis-Menten kinetics. Introduction
of the catalyst within streptavidin con-
tributes to improve both the activity (e.g.
phenomenon of protein-accelerated ca-
talysis, compare [Rh(COD)(Biot–1)]
+
,
k
cat
3.06 min
–1
, K
M
7.38 mM, with
[Rh(COD)(Biot–(R)-IV–1)]
+
⊂WT Sav,
k
cat
12.30 min
–1
, K
M
4.36 mM) and the
selectivity.
[42]
v) Although most ligand–protein com-
binations afford comparable levels of
conversion and enantioselectivity for
both substratres, certain combinations
yield substrate specific artificial hydro-
genases (Table 1, entry 6).
Having demonstrated the potential of ar-
tificial metalloenzymes for the reduction of
N-protected dehydroaminoacids, we turned
our attention towards organometallic-cata-
lyzed reactions where the enantiodiscrimi-
nation step occurs without coordination of
one of the reactants to the metal center. We
anticipated that incorporation of the metal
complex within a protein environment may
steer the enantioselection without requiring
transient coordination to the metal. In this
context, we selected palladium-catalyzed
asymmetric allylic alkylation, ruthenium-
catalyzed transfer hydrogenation and the
vanadyl-catalyzed sulfoxidation reaction.
Indeed, these reactions are believed to pro-
ceed without prior coordination of the soft
nucleophile, the prochiral ketone or the
prochiral sulfide respectively (Fig. 4).
Artificial Allylic Alkylases
In the field of C–C bond forming reac-
tions, palladium occupies a priviledged po-
sition.
[46]
In this context, asymmetric allylic
alkylation attracted our interest due to its
unique outersphere attack of the malonate
on the η
3
-coordinated 1,3-diphenylallyl
moiety.
[47]
Following the above-described che-
mogenetic optimization procedure, we
screened twenty-one biotinylated ligands
in conjunction with twenty two (strept)-
avidin isoforms for the allylic aklylation
of 1,3-diphenylallyl acetate. Addition of
didodecyldimethylammonium bromide
(DMB) allowed a significant improvement
of the yield of alkylation product – over the
hydrolysis product, 1,3-diphenylallylalco-
hol, formed predominantly in the absence
of DMB – (Scheme 2). This screening re-
vealed the following trends:
[19]
i) The nature of the spacer plays a critical
role in conferring activity to the artifi-
cial alkylase. In most cases and despite
the addition of DMB, the hydrolysis
product was formed predominantly. The
best spacers are conformationally con-
strained: either proline IV or o-amino-
benzoate II
o
(Table 2, entries 1–3).
ii) Despite the presence of chaotropic
agents (surfactant and basic pH), the ar-
tificial metalloenzymes behave remark-
ably well. While the high pH is required
for the reaction to proceed, the reaction
carried out in the absence of DMB leads
to a significant erosion of the conver-
sion, with only a modest increase in se-
lectivity (Table 2, entries 3, 4).
iii) As previously observed for the hydro-
genation reaction, conformationally
constrained ligands confer improved
organic solvent tolerance. Reactions
with [Pd(η
3
-allyl)(Biot–II
o
–1)]
+
⊂
S112A Sav can be performed in 45%
dmso without addition of DMB (Table
2, entry 5).
[48]
iv) Again here, the versatility of the chemi-
cal optimization allowed the rapid iden-
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Fig. 4. Postulated transition states of homogeneous enantioselective
reactions which proceed without coordination of one of the substrates
to the metal center: allylic alkylation (a), transfer hydrogenation (b) and
sulfoxidation (c)
NHAc
COOH
[Rh(COD)
2
]BF
4
(0.9 mol%)
Biot-spacer-1 (1.0 mol%), (strept)avidin (0.33 mol%)
0.1 M MES buffer, H
2
(5 bar), RT, 15 h
COOH
H
NHAc
R
R = H, Ph
R
R = H N-AcAla
R = Ph N-AcPhe
Scheme 1. Substrates and operating conditions used for the hydrogenation
reaction catalyzed by artiﬁcial metalloenzymes based on the biotin-avidin
technology
Table 1. Selected results obtained for the hydrogenation reaction
Entry Ligand Protein
ee [%]
a
N-AcAla
Conv. [%]
b
N-AcAla
ee [%]
N-AcPhe
Conv. [%]
b
N-AcPhe
1 Biot-1 WT Sav 94 quant. 93 84
2 Biot-1 S112A 93 quant. 94 94
3
c
Biot-(R)-IV-1 S112W –94 98 –94 86
4
d
Biot-(R)-IV-1 WT Sav –87 quant. –91 quant.
5
e
Biot-(R)-IV-1 WT Sav –87 quant. –86 94
6 Biot-(R)-IV-1 S112E –79 quant. –55 16
a
Positive ee values in favour of the (R)-enantiomer, negative ee values in favour of the (S)-
enantiomer;
b
quant. = Quantitative.
c
Biphasic;
d
27% DMSO;
e
45% DMSO.
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tification of an active biotinylated li-
gand. The genetic optimization can be
regarded as a fine-tuning step: whereas
most streptavidin isoforms yielded
(R)-alkylation products in conjunc-
tion with [Pd(η
3
-allyl)(Biot–II
o
–1)]
+
,
S112Q clearly stands out as it affords
the (S)-alkylation product (Table 2, en-
try 6).
Artificial Transfer Hydrogenase
The asymmetric transfer hydrogenation
of ketones is an effective way to prepare
enantiopure alcohols.
[49]
We were attracted
to this reaction as we anticipated that one
could exploit the reversibility of the reac-
tion to perform either the enantioselective
reduction or the kinetic resolution of race-
mic alcohols via oxidation.
[50]
This behav-
iour is reminiscent of alcohol dehydroge-
nases which can operate either as oxidases
or reductases.
[2]
Incorporation of a biotinylated d
6
-pi-
ano-stool complex bearing a biotinylated
aminosulfonamide ligand into streptavi-
din afforded artificial transfer hydroge-
nases for the reduction of acetophenone
derivatives. A buffered solution (pH 6.25)
containing sodium formate as a hydrogen
source proved best in terms of conversion
and selectivity. Unexpectedly, the perfor-
mance of the artificial metalloenzyme was
improved by raising the temperature to
55 °C.
[18,39,51]
A combined chemo-genetic
procedure combining twenty-one piano-
stool complexes with the twenty S112X
Sav isoforms allowed the activity and the
selectivity of these hybrid catalysts for the
reduction of prochiral ketones to be opti-
mized (Scheme 3). The following trends
were identified:
[52]
i) Only catalysts bearing the para-substi-
tuted spacer biot–III
p
–2 afforded any
significant level of conversion.
ii) Ruthenium-based catalysts [Ru(η
6
-
arene)H(Biot–III
p
–2)] outperformed
either rhodium or iridium based systems
[M(η
5
-C
5
Me
5
)H(Biot–III
p
–2)].
iii) Under otherwise identical condi-
tions, the p-cymene [Ru(η
6
-p-cymene)
H(Biot–III
p
–2)] and the benzene
[Ru(η
6
-p-benzene)H(Biot–III
p
–2)]
complexes afforded opposite enantio-
mers (Table 3, entries 1, 2).
iv) Various acetophenone derivatives could
be reduced with good enantioselectiv-
ites up to 97% ee for (R)-products and
92% ee for (S)-products (Table 3, en-
tries 3, 6).
v) In contrast, the selectivities obtained
for the reduction of dialkylketones re-
mained modest (Table 3, entries 4, 5).
In the context of transfer-hydrogena-
tion, dialkylketones are challenging sub-
strates as the major contribution to the
enantiodiscrimination event is believed to
be C–H······π interactions between the η
6
-
bound arene and the phenyl moiety on the
prochiral substrate (Fig. 4).
[53–55]
We an-
ticipated that the introduction of additional
sites of mutation in the proximity of the pia-
no-stool moiety may allow this challenge to
be addressed. For this purpose, we invested
considerable effort into crystallizing the
most promising (R)- and (S)-selective arti-
ficial metalloenzymes: [Ru(η
6
-p-benzene)
Cl(Biot–III
p
–2)] ⊂ S112K Sav and [Ru(η
6
-
p-cymene)Cl(Biot–III
p
–2)] ⊂ S112A Sav.
We were fortunate to succeed in crystalliz-
ing the former and its structure is depicted
in Fig. 5.
[51]
Based on this structure, we per-
Biot-spacer-1 (0.048 equiv)
(strept)avidin (0.014 equiv)
K
2
CO
3
(5 equiv)
DMB (2 equiv)
H
2
O/DMSO (10/1), RT,16 h
OAc
MeO
2
C CO
2
Me
Dimethylmalonate: 5 equiv
[Pd(R
2
allyl)Cl]
2
(0.02 equiv)
1 equiv
Scheme 2. Operating conditions used for the asymmetric allylic alkylation
catalyzed by artiﬁcial metalloenzymes based on the biotin-avidin
technology.
Table 2. Selected results obtained for the asymmetric allylic alkylation
Entry Ligand Protein ee [%]
a
Conv. [%]
1 Biot-(R)-IV-1 S112G V47G –82 92
2 Biot-II
o
-1 S112G 88 95
3 Biot-II
o
-1 S112A 90 95
4
b
Biot-II
o
-1 S112A 93 20
5
b,c
Biot-II
o
-1 S112A 95 90
6 Biot-II
o
-1 S112Q –31 96
a
Positive ee values in favour of the (R)-enantiomer, negative ee values in favour of the (S)-
enantiomer.
b
No DMB was added.
c
The reaction was performed in 45% DMSO.
HCOONa, B(OH)
3
MOPS buffer (pH
initial
6.25)
55
o
C, 64 h
R
large
R
small
O
R
large
R
small
OH
N
OH
5 6 7
O
OH
R
OH
R = Br, 3
R = Me, 4
OH
8
[Ru(η
6
-arene)H(Biot-III
p
-2)] (1%)
(strept)avidin (0.33%)
OH
η
6
-arene: η
6
-p-cymene; η
6
-benzene
Scheme 3. Substrates and operating conditions used for the transfer
hydrogenation catalyzed by artiﬁcial metalloenzymes based on the biotin-
avidin technology.
Table 3. Selected results obtained for the transfer hydrogenation using [Ru(h
6
-p-benzene)Cl(Biot–
III
p
–2)]
Entry h
6
-Arene Protein Product ee [%]
a
Conv. [%]
1 p-cymene S112A 4 91 98
2 benzene S112T 3 –55 90
3 p-cymene S112Y 6 97 79
4 p-cymene S112A 8 48 98
5 p-cymene S112A 7 69 97
6 p-cymene S112A K121N 5 –92 quant.
b
7 p-cymene S112A K121T 7 90 quant.
b
8 p-cymene S112A K121T 8 88 99
a
Positive and negative ee values correspond to the R and S enantiomers, respectively;
b
Quantitative
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formed an additional round of mutations,
concentrating on the close-lying K121 and
L124 residues and using WT Sav, S112K
and S112A as background, thus affording
a total 120 Sav isoforms. In order to speed
up the optimization process, a straightfor-
ward Sav immobilization procedure was
implemented.
[51]
For this purpose, com-
mercially available biotinylated sepharose
was added to the supernatant of the E. coli
lysed cell cultures. After centrifugation,
the immobilized Sav mutants, which on
average possessed three remaining biotin-
binding sites, were treated with an excess
of [Ru(η
6
-arene)Cl(Biot–III
p
–2)], washed
and tested in the presence of Sav. This sec-
ond optimization round allowed to iden-
tify artificial transfer hydrogenases which
displayed much improved selectivities to-
wards dialkylketones (Table 3, entries 7,
8).
Having developed an efficient artificial
transfer hydrogenase, we attempted to ap-
ply the same methodology to the reverse
reaction: the kinetic resolution of racemic
alcohols. To our disappointment, we were
forced to use strong oxidizing agents (e.g.
t-BuOOH rather than acetone, in the spirit
of an Oppenauer-type mechanism) to drive
the reaction to completion.
[56]
We speculate
that, in the presence of water, the ruthe-
nium is unable to abstract the β-hydrogen
on the prochiral alcohol.
Despite the excitement generated by
the X-ray structure, the localization of the
biotinylated metal complex within the pro-
tein environment was a source of disap-
pointment. Indeed, we anticipated that the
active catalyst would be located inside the
biotin-binding pocket of Sav rather than
on the surface of the protein. To overcome
this problem we tested whether the polar
residues present within the biotin-binding
pocket itself (Fig. 2) may be capable of
binding a polar coordination complex.
With this goal in mind, we tested the cata-
lytic potential of vanadyl as a catalyst.
[57]
Enantioselective Sulfoxidation Based
on Vanadyl-loaded Streptavidin
Addition of vanadyl sulfate to Sav af-
fords an artificial oxidase for the sulfoxi-
dation of prochiral sulfides. The system is
most efficient at low pH (2.2) and organic
peroxides are required for efficient cataly-
sis (Scheme 4). From the screening, the
following trends emerge:
[21]
i) A variety of prochiral sulfides are oxi-
dized to the corresponding sulfoxides
with no overoxidation.
ii) At room temperature and relying on
0.02 equivalents vanadium, the conver-
sions are complete in most cases and
the (R)-selectivities often exceed 90%
(Table 4, entries 1–5).
iii) Since there is no ligand, the system
cannot be optimized chemically.
iv) In the presence of biotin-loaded Sav,
the sulfoxidation with VOSO
4
affords
racemic product, suggesting that vana-
dium cannot compete for binding with
biotin (Table 4, entry 6).
v) It is widely recognized that residue
D128 Sav is most important in biotin-
binding (see Fig. 2).
[58]
The mutant
D128A Sav affords racemic sulfoxide,
Fig. 5. Close-up view of the X-ray crystal structure of [Ru(η
6
-p-benzene)
Cl(Biot–III
p
–2)] ⊂ S112K Sav. The ruthenium position is partially occupied
(20%). The absolute conﬁguration at Ru is (S).
thus suggesting that the vanadyl moi-
ety is located within the biotin-binding
site (Table 4, entry 7).
vi) Replacement of the L3,4-loop of Sav by
the corresponding L3,4-loop of Avi af-
fords a chimaeric protein (Aviloop)
[59]
with improved properties for the sul-
foxidation of dialkylsulfides (Table 4,
entries 8).
HCl / KCl 0.05 M, pH 2.2
[Substrate] = 0.01 M
t-BuOOH 5 equiv, RT
VOSO
4
(2%), (strept)avidin (1%)
R
large
S
R
small
R
large
S
R
small
O
:
Me
S
S
S
MeO
S
O
O
O
O
: :
:
:
9 10 11 12 13
S
O
:
:
:
Scheme 4. Substrates and operating conditions used for sulfoxidation
catalyzed by artiﬁcial metalloenzymes based on vanadyl-loaded
streptavidin.
Table 4. Selected results obtained for the sulfoxidation reaction
Entry protein Vanadium source Product ee [%]
a
Conv. [%]
1 WT Sav VOSO
4
9 87 96
2 WT Sav VOSO
4
10 90 quant.
b
3 WT Sav VOSO
4
11 93 53
4 WT Sav VOSO
4
12 90 96
5 WT Sav VOSO
4
13 86 61
6 WT Sav + biotin VOSO
4
10 0 96
7 D128A VOSO
4
10 0 97
8 Aviloop
c
VOSO
4
13 90 54
a
(R)-enantiomer produced preferentially;
b
Quantitative;
c
see ref. [59]
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Conclusions and Outlook
As summarized in this review, artificial
metalloenzymes based on the biotin-avidin
technology have developed into a versatile
approach to enantioselective catalysis. In
many cases, selectivities exceeding 92% ee
could be obtained, relying on a chemogenetic
optimization strategy. Such hybrid catalysts
display features which are reminiscent of
both homogeneous and enzymatic catalysis.
Although the reactions implemented so far
are limited to model systems, we believe that
these catalysts will reveal their full potential
for transformations for which there exists to
date no good homogeneous catalyst. In this
context, our current efforts are directed to-
wards the hydroxylation of alkanes (where
overoxidation is difficult to prevent with
homogeneous systems) as well as highly
sequence-specific DNA hydrolysis.
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